BioSpace News Archive

Vitae Industries (“Vitae”) announced today pharmacy and pharmaceutical industry veteran James “Jim” Hussey, RPh has joined its Board as an independent director. Jim has been working closely with the Vitae team for the past year. Vitae is bringing next generation pharmacy compounding technology and solutions to pharmacies, hospi

- Technology transfer of UltraPorator to clinical sites dosing UltraCAR-T successfully completed - - UltraPorator poised to transform manufacturing and accessibility of CAR-T therapies for cancer patients - [15-October-2020] GERMANTOWN, Md. , Oct. 15, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the develo

98point6 , an on-demand digital primary care service that delivers personalized consultation, diagnosis and treatment to patients across the country, today announced a $118 million Series E fundraising round to further support its growth and success. The

Healthcare Services Group, Inc. (NASDAQ:HCSG) (the “Company”) announced today that it is scheduled to release its earnings results for the three months ended September 30, 2020, on Wednesday, October 21, 2020 at 7:00 a.m. Eastern Time. In conjunction with its release, the Company will host a conference call on Wednesday, Octo

Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. The CTS Rotea system is the first Gibco instrument for cell therapy processing applications and

GT Biopharma, Inc. is pleased to announce its abstract “GTB-3550 TriKE™ for the Treatment of High-Risk Myelodysplastic Syndromes and Refractory/Relapsed Acute Myeloid Leukemia Safely Drives Natural Killer Cell Proliferation At Initial Dose Cohorts” has been selected by the Program Committee for presentation in an Oral Session at the 62nd American Society of Hematology Annual Meeting and Exposition

Advaxis , Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it will present an ePoster at the 35 th Annual Meeting of the Society for Immunology of Cancer (SITC 2020) to be held virtually November 9-14, 2020. Title: “Phase 1/2 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Sub

Clinical and Translational Research Collaboration Will Evaluate Multiple AlloCAR T Candidates Across the Allogene Portfolio Targeting Multiple Tumor Types

-- mRNA-based vaccine candidate MRT5500 induced potent neutralizing antibodies against SARS-CoV-2 in preclinical studies -- -- Two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients -- -- Phase 1/2 clinical trial anticipated to begin in the fourth quarter of 2020 --

BioLife Sciences Inc. (OTCPK:BLFE) announced today the launch of their new antimicrobial air filter technology. BioLife Antimicrobial Air Filters provide consumers with the ability to help sanitize the air in their homes or workspaces, while providing continuous, long-lasting protection for months. The fabric-based BioLife Antimicrobial Copper Air Filter utilizes the company’s proprietary Mfusion Technology. Mfusion Te